Active Not Recruiting PHASE4 INTERVENTIONAL 1-arm NCT06637072

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC

Sponsor: argenx

Conditions Chronic Inflammatory Demyelinating Polyneuropathy

Interventions Efgartigimod PH20 SC

Updated 6 times since 2024 Last updated: Feb 6, 2026 Started: Dec 10, 2024 Primary completion: Feb 23, 2026 Completion: Feb 23, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Inflammatory Demyelinating Polyneuropathy, this trial is ongoing. The trial is conducted by argenx and has accumulated 6 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE4
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE4
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE4
Feb 2025 — Aug 2025 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Nov 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

argenx

Data source: argenx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Chattanooga, United States , Chicago, United States , Cypress, United States , Dallas, United States , Lafayette, United States , Maitland, United States , Miami, United States , Nashville, United States , Plymouth, United States and 2 more locations